Connor, Clark & Lunn Investment Management (CC&L)’s Akero Therapeutics AKRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.21M | Buy |
+41,328
| New | +$2.21M | 0.01% | 827 |
|
|
2024
Q4 | – | Sell |
-10,159
| Closed | -$291K | – | 1394 |
|
|
2024
Q3 | $291K | Sell |
10,159
-59,836
| -85% | -$1.72M | ﹤0.01% | 1247 |
|
|
2024
Q2 | $1.64M | Sell |
69,995
-32,607
| -32% | -$765K | 0.01% | 708 |
|
|
2024
Q1 | $2.59M | Buy |
102,602
+92,587
| +924% | +$2.34M | 0.01% | 608 |
|
|
2023
Q4 | $234K | Sell |
10,015
-8,048
| -45% | -$188K | ﹤0.01% | 1230 |
|
|
2023
Q3 | $914K | Sell |
18,063
-5,675
| -24% | -$287K | ﹤0.01% | 848 |
|
|
2023
Q2 | $1.11M | Buy |
+23,738
| New | +$1.11M | 0.01% | 769 |
|
|
2022
Q4 | – | Sell |
-70,253
| Closed | -$2.39M | – | 1188 |
|
|
2022
Q3 | $2.39M | Buy |
70,253
+39,162
| +126% | +$1.33M | 0.02% | 460 |
|
|
2022
Q2 | $294K | Buy |
+31,091
| New | +$294K | ﹤0.01% | 867 |
|